Osteoporosis
- 30 September 2003
- journal article
- review article
- Published by Elsevier BV in Medical Clinics of North America
- Vol. 87 (5), 1039-1063
- https://doi.org/10.1016/s0025-7125(03)00065-8
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled StudyMayo Clinic Proceedings, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Alendronate Increases Bone Mass and Reduces Bone Markers in Postmenopausal African-American WomenJournal of Clinical Endocrinology & Metabolism, 2002
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with OsteoporosisJournal of Clinical Endocrinology & Metabolism, 2002
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- Alendronate Does Not Block the Anabolic Effect of PTH in Postmenopausal Osteoporotic WomenJournal of Bone and Mineral Research, 1998
- Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis FoundationJournal of Bone and Mineral Research, 1997
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- Risk Factors for Falls among Elderly Persons Living in the CommunityNew England Journal of Medicine, 1988